Neurobiological Tech (NTII) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurobiological Tech (NTII)

NTII 0.0001000

0.0%

Mar 7 3:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Dr. John M. de Castro who wrote (649)	8/16/1999 10:37:00 AM
From: BRAVEHEART	Read Replies (1) of 1494

TREATMENT vrs CURE Hi John, Am I alone in thinking that NTI's approach is more like asprin in treating DPN's painful symptoms. This to me offers a higher chance of success as opposed to Pfizers more aggressive attempt to find a cure for the condition through nerve regeneration. "Pfizer said part of the problem with Alond was in finding a way to detect whether nerves damaged by diabetes were growing back. Pfizer was taking biopsies of patients' nerves to measure any difference." "Diabetes advocates said Pfizer's announcement, which was made late Thursday, was a setback.''Its always disappointing when you hope something is going to be a cure'' Marian Parrot, a spokeswoman for the American Diabetes Association, said Friday." Some further speculations JOHN. Notice the article's reference to the number of Big Pharmas who still have announced late stage research in this area. One company, Warner-Lambert. "results of those studies are not expected for at least a year." Now let's see John. If you were a CEO of Big Pharma. You knew a competitor like Pfizer were expected to announce results on a product relatively soon which would essentially lock up a specific market ie DPNs. At the same time you had the opportunity to collaborate with a biotech for a product to treat the disease state. Would you: {A} Drag your feet for a few months if possible. Or {B}Throw all caution to the wind and go under contract to invest millions in a product. While NTII's product has it's own intrinsic risks the market risk ( from a competitor approach ) has just been reduced significantly IMO. Especially in light of the fact that Warner-Lamberts results are close to a year away. With reduced competitor risk comes enhanced potential. Personally if I were a CEO looking to partner Memantine I would be enticed by todays news. PS: I made it in through a back door. SI has been slow in responding to my problems with the three-D site. The new page prevents me from accessing my log-in ability. BEST WISHES Jeffrey

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next